ArticleCureus2025
Digoxin Toxicity in Renal Failure: Resolution With Plasma Exchange After Fab Therapy Failure.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research and Application of the Polyene Macrolide Antibiotic Nystatin.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digoxin toxicity is a serious clinical concern, particularly in patients with chronic kidney disease (CKD), due to impaired renal clearance and the potential for both chronic tissue accumulation and acute overdose. Standard therapy with digoxin-specific antibody fragments (Fab) may be insufficient in cases with large tissue digoxin burdens and in patients with acute renal failure, as the delayed clearance of digoxin-Fab complexes can result in complex dissociation and rebound toxicity. We present a unique case of a 73-year-old woman with acute-on-chronic digoxin toxicity in the setting of acute renal failure who exhibited persistent toxicity symptoms despite Fab therapy. The patient underwent plasma exchange (PLEX) to remove lingering digoxin-Fab complexes and remaining free digoxin, resulting in successful clinical resolution and no disease recurrence. This case highlights the use of PLEX as a potential salvage therapy for patients with chronic digoxin toxicity and renal impairment who exhibit persistent toxicity symptoms despite treatment with Fab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.